Primary breast cancer
Conditions
Brief summary
Immunohistochemistry fraction of Estrogen Receptor is changed from 0% to 2% or more after imatinib treatment, Immunohistochemistry fraction of Estrogen Receptor is changed from 1-9% to ≥10% after imatinib treatment, Immunohistochemistry fraction of Estrogen Receptor 1-9% increase with at least 2%, coupled with a significant increase luminal gene transcripts
Detailed description
Safety analyses according to common terminology criteria for adverse events (CTCAE) v.5: up to 30 days after the last dose of imatinib., Identification of predictive markers for conversion by evaluation of molecular characteristics (gene expression profiles, intrinsic subtypes and proliferation) and immune response in tissue and blood before start of imatinib and in the surgical specimen.
Interventions
DRUGIMATINIB
Sponsors
Vaestra Goetalandsregionen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Safety analyses according to common terminology criteria for adverse events (CTCAE) v.5: up to 30 days after the last dose of imatinib., Identification of predictive markers for conversion by evaluation of molecular characteristics (gene expression profiles, intrinsic subtypes and proliferation) and immune response in tissue and blood before start of imatinib and in the surgical specimen. | — |
Primary
| Measure | Time frame |
|---|---|
| Immunohistochemistry fraction of Estrogen Receptor is changed from 0% to 2% or more after imatinib treatment, Immunohistochemistry fraction of Estrogen Receptor is changed from 1-9% to ≥10% after imatinib treatment, Immunohistochemistry fraction of Estrogen Receptor 1-9% increase with at least 2%, coupled with a significant increase luminal gene transcripts | — |
Countries
Sweden
Outcome results
None listed